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Abstract--The human monoblastoid tumor cell line U937 was induced to differentiate along the 
monocyte/macrophage lineage by treatment with 5 x 10 -9 M 12-O-tetradecanoyl phorbol-13-acetate 
(TPA). Between 2 h and 4 h following TPA-treatment U937 cells tarted to release significant amounts 
of TNF-,x which remained etectable until 8--10 days. A significant IL-1 fl release was measured 24 h- 
48 h post stimulation and increased levels of IL-1/3 persisted until 20-22 days of culture. In contrast 
no release of either IL-1 a or IL-6 could be detected with 5 x 10 -9 M TPA during the whole time 
course of the experiments. The sequential induction of TNF-o~ and IL-1/3 appeared to be independently 
regulated since TNF-a release was not required for the onset of IL-1 fl production. Northern-blot 
analysis confirmed the sequential induction and the long term expression of TNF-oc and IL-1 /3 
mRNAs. Western-blot analysis predominantly showed a high molecular weight IL-1 /5 protein of 
about 35 kD. Further investigations on the regulation of cytokine production and release by TPA- 
differentiated U937 cells revealed that TNF-,~ and IL-I/3 synthesis was not influenced by exogenously 
added rhTNF-cr or PGE,, whereas rhy-IFN specifically enhanced the IL-1 /5 production. Thus, the 
regulation and intracellular processing of cytokines generated by differentiating U937 cells shows 
some differences when compared to mature monocytes/macrophages which may be related to the 
tumorigenic origin of U937 cells or to an incomplete differentiation. 
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INTRODUCTION 
CVTOKINES including TNF-o~, IL-1 and IL-6 play a 
pivotal role in immune reactions and regulate the 
growth and the activity of many cells in inflammation 
[1,2]. 
TNF, IL-1 and IL-6 are predominantly secreted 
by activated monocytes/macrophages as part of a 
general inflammatory response. These cytokines are 
acting (in oivo) as amplification and differentiation 
factors in a cascade of inflammatory events. They 
can also be released from in vitro induced cells in 
culture. Many studies have investigated the regu- 
lation of TNF-c~, IL-1 and IL-6 in macrophage cell 
lines or macrophages stimulated with various 
inflammatory agents [3-6]. 
Abbreviations: TPA-U937, U937 cells treated for 72 h 
with 5 nM TPA; TPA/IFN-U937, TPA-U937 treated for 
24 h with 100 U/ml rhy-IFN; TPA/Dex-U937, TPA-U937 
treated for 24 h with 10 -~ M dexamethasone. 
Correspondence to:Dr Rail Hass, Department of Clini- 
cal Pharmacology, Dana-Farber Cancer Institute, 44 
Binney Street, Boston, MA 02115, U.S.A. 
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The human monoblastoid U937 tumor cell line is 
widely used as a model for a differentiation of pre- 
cursors into macrophage-like c lls [7]. U937 cell dif- 
ferentiation can be induced by incubation with 
different agents, including retinoic acid [8], vitamin D 
derivatives [9], cytokines [10] and phorbol esters [11]. 
In the present studies the phorbol ester TPA was used 
which resulted in a differentiation of each U937 cell 
since no TPA-resistant subclone could be isolated 
from the cultures. TPA-treatment of U937 cells is 
accompanied by several morphological nd functional 
changes uch as alterations incell shape and cessation 
of proliferation. These include a down-regulation of
transferrin-receptors, a reorganization of actin and 
vimentin filaments and a significant expression of 
newly synthesized surface ntigens [12]. Furthermore, 
TPA-induced monocytic differentiation of U937 cells 
is associated with a rapid de novo synthesis of cellular 
lectins and glycoproteins [13] including a markedly 
increased expression of the leukocyte function anti- 
gens LFA-1 (CDl la) ,  CR3/MAC1 (CDl lb) ,  
gp 150,95 (CD 11 c) and the ~subunit CD 18. Although 
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these cells acquire many functional parameters in 
common with monocytes/macrophages during the dif- 
ferentiation process we have previously shown that 
TPA-treated U937 cells fail to exhibit some important 
properties associated with mature monocytes includ- 
ing the expression of HLA-class II or CDl4  antigens. 
TPA-treated U937 cells were therefore characterized 
as immature macrophage intermediate rather than 
terminally differentiated cells [12]. 
Here we investigated the regulation of cytokine 
production during differentiation of human mono- 
blastoid U937 tumor cells. Our observations dem- 
onstrate that during differentiation induced with 
5 nM TPA the U937 cells sequentially acquire the 
capacity to produce and release TNF-cr and IL-l fl, 
but not IL-1 tr or IL-6. Both, the intracellular IL-1 
/3 as well as the released molecule showed a pre- 
dominant form of approximately 33-35kD. In 
addition, the different regulation of TNF-cr and IL- 
l /3 release by exogenous rhTNF-tr, rhy-IFN and 
PGE2 in differentiating U937 cells was found to be 
partially different from that reported for activated 
monocytes/macrophages. Therefore, differentiating 
U937 cells provide an excellent model to study cyto- 
kine regulation within different steps of development 
along the monocytic pathway. 
MATERIALS  AND METHODS 
Cell culture 
U937 cells were cultured in RPMI 1640 medium and 
differentiated with 5 x 10 -9 M 12-O-tetradecanoyl phor- 
bol-13-acetate (TPA) (Sigma Chemie GmbH, Deisen- 
hofen, F.R.G.) for 3 days as described elsewhere [13]. A 
long term culture of TPA-differentiated U937 cells (TPA- 
U937) was performed by replacing the culture medium 
without TPA every 3 days. These TPA-U937 were cultured 
for 2-3 weeks without any significant changes in cell mor- 
phology and adherence. Cell viability was assessed by 
trypan-blue exclusion in the non-adherent untreated U937 
cells and by acridine orange staining of the adherent TPA- 
U937. At every time point of the experiments he viability 
of all cell cultures was greater than 95%. 
[3H]TPA was purchased from NEN, Dreieich, F.R.G. 
TPA-differentiated U937 cells (TPA-U937) were treated 
with 10 -6 M dexamethasone (Merck, Darmstadt, F.R.G.) 
for 24 h (TPA/Dex-U937). In similar experiments TPA- 
U937 cells were also treated with 100 U/ml rh~,-IFN (kindly 
provided by Dr Otto, Fraunhofer Institut fiir Toxikologie, 
Hannover, F.R.G.) for 24h (TPA/IFN-U937) or with 
2 ng/ml PGE 2 (Sigma) for 24 h. 
Detection of TNF-o: and IL-I fl in culture medium 
Radioimmunoassays of cell supernatants from both U937 
control cells and stimulated U937 cells were performed 
using specific antibodies without cross-reactivities to other 
known cytokines as described elsewhere for TNF-a' [14]. 
IL-I o~ [15] and IL-I fl [16]. 
Biological activity of TNF-containing samples was 
assayed by measuring neutral red dye uptake of L929 cells 
using the method as described by Wallach [17]. IL-1- 
activity was examined with the mouse thymoma EL4.16 
cell line which can be stimulated by IL-l to produce IL-2. 
These supernatants were transferred to an IL-2-dependent 
cytotoxic-T-lymphocyte lin (CTLL) and the proliferation 
of these CTLL cells was measured by [3H]thymidine incor- 
poration. The biological activities (U/ml) were calculated 
in (pg/ml) by the specific activities: 1 U (TNF-tr or IL-I 
/3) = 50 pg. 
As controls rhTNF-oc (Boehringer Mannheim GmbH, 
Mannheim, F.R.G.), rhIL-1 tr and rhIL-1 fl (both from 
Biogen Inc., Geneva, Switzerland) were used in the appro- 
priate assay systems. 
FPLC-separation of proteins released into the culture 
medium 
TPA/IFN-U937 were incubated for 4 days with FCS-free 
culture medium. The medium was changed and collected 
every 24 h. This medium was concentrated 1:ll~d0 in an 
ultrafiltration chamber (Amicon GmbH, Witten, F.R.G.) 
using a membrane with molecular weight cut off of approxi- 
mately 5 kD (YM5 membrane, Amicon). The concentrate 
was applied on a FPLC superose 12 column (Pharmacia, 
Freiburg, F.R.G.) pre-equilibrated with PBS. Fractions 
were collected in 500 p,I aliquots. To estimate the molecular 
weight of the protein containing fractions, the FPLC 
column was calibrated by using the standard proteins a- 
amylase (200 kD), BSA (67 kD), ovalbumin (43 kD), car- 
boanhydrase (29 kD), cytochrome C (12 kD) and aprotinin 
(6.5 kD) (all from Sigma). 
Western-blot analysis of IL-l fl proteins 
For Western-blot analysis the homogenate, cytosol and 
membrane fraction was prepared from U937, TPA-U937, 
TPA/Dex-U937 and TPA/IFN-U937. The cells of each 
treatment group were washed twice with PBS and disrupted 
in PBS by sonication (3 × 5 s/50W) with a labsonic cell- 
disrupter (Braun AG, Melsungen, F.R.G.). The cell frag- 
ments were centrifuged (900 × g/10 min) to remove nuclei. 
The supernatant was termed as homogenate. For further 
fragmentation, this cell homogenate was centrifuged 
(120000 ×g/30min) in a Beckmann LS-70M ultracen- 
trifuge (Beckmann Instruments GmbH, M0nchen, 
F.R.G.). The resulting supernatant was used as cytosol 
and the pellet after resuspending in PBS was used as 
membrane fraction. 
Homogenate, cytosol and membrane fraction of all 
samples were adjusted to the same protein concentration 
using the microtiter Bradford protein assay [18, 19] with 
BSA as standard. Aliquots containing 30lag of protein 
were run on a 10% polyacrylamide SDS-gel [20] and 
transblotted toan immobilon-P membrane (Millipore Inc., 
Bedford, MA) in ice-cold blotting-buffer (15mM Tris, 
pH 8.3; 120 mM glycine; 20% (v/v) methanol) at 200 mA 
for 1 h. After blotting, the protein standards on the ref- 
erence lane of the blot were stained with amido black. The 
membrane was thcn incubated in blocking-buffer (100 mM 
Tris, pI-t 7.4; 0.9% (w/v) NaCI; 0.02% (w/v) NAN3; 5% 
(w/v) low fat dry milk) for 4 h to block non-specific binding 
sites. Thereafter, a monoclonal mouse anti-rhlL-1 [,3 (pep- 
tide: 165-186) antibody (kindly provided by Dr H. 
Herzbeck, Forschungsinstitut Borstel, F.R.G.) was used 
in blocking-buffer for 12 h. Following 3-4 washes of the 
blot with blocking-buffer for 10min, an [1251]-Iabeled rabbit 
anti-mouse lgG (Dacopatts GmbH, Hamburg, F.R.G.) 
was applied in the same buffer for a further 12 h. After 
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removing the iodinated antibody the blots were washed 8- 
10-times in 100 mM Tris, pH 8.0 to remove non-specifically 
bound radioactivity. The blots were air dried and exposed 
to an X-ray film. 
Northern-blot analysis of cytokine mRNAs 
U937 cells and TPA-U937 cells cultured for the time 
points indicated (10 7 cells per culture) were solubilized 
with l ml 7.6 M guanidine-HCI in0.1 M potassium acetate 
buffer pH 5.11 and DNA was sheared by 5-times aspiration 
through a 21 gauge needle. Isolation f total RNA was 
performed according to Khand)ian [21]. The RNA was 
electrophoresed on 1% agarose/formaldehyde gels, trans- 
ferred to nylon filters and hybridized as described by 
Chirgwin et al. [221. 
A TNF-cDNA probe (BASF AG, Ludwigshafen, 
F.R.G,) (425 bp PstI-fragment of the non-translated 3'- 
region of human TNF), the IL-I a~ and IL-1 /3 probes 
(generous gift from Dr U. Gubler, ttoffmann LaRoche, 
Nutley, N.J.) (460 bp human IL-I a" EcoRI-BamHl cDNA 
fragment and a 530 bp human IL-1/3 BamHI-NdeI cDNA 
fragment of the coding region, respectively) and the IL-6 
probe (kindly provided by Dr M. Revel, Weizmann Insti- 
tute, Rehovot, Israel) were labeled by the random primer 
method [23[ and exposed toX-ray film at -70°C for 1-3 
days. 
RESULTS 
Characterization of monocytic markers and growth 
arrest during TPA-induced monocytic differentiation 
of U937 cells 
To determine differentiation of U937 cells after 
treatment with 5 nM TPA we measured both the 
expression of some markers associated with the 
monocytic phenotype and cell growth. The capacity 
to generate oxygen-derived free radicals was detected 
by reduction of nitroblue-tetrazolium (NBT). After 
72 h of TPA-treatment approximately 14% of the 
cells showed positive staining with NBT. Further- 
more, measurement of the monocyte specific marker 
a-naphthylacetate esterase revealed a rapid 
expression by 84% of U937 cells after 24 h of incu- 
bation with 5 nM TPA. These levels were elevated 
to nearly l(X)% of the TPA-treated cell population 
after 72 h. In contrast, untreated U937 control cells 
showed neither positive staining with NBT nor 
expression of o~-naphthylacetate est rase (Table 1). 
According to the expression of these monocytic 
markers, differentiating U937 cells ceased to grow as 
measured by [~H]thymidine incorporation. After 72 h 
no proliferation could be detected in TPA-treated 
U937 cells (Table 1). 
These data are in concert with extensive studies 
on monocytic surface receptor expression performed 
previously under the same experimental conditions 
[12] and it is thercfore suggested that U937 cells 
treated with 5 nM TPA were differentiated along the 
monocyte/macrophage lineage. 
Release of TNF-tr and IL-I fl from TPA-treated U937 
cells 
U937 cells released increasing levels of both TNF- 
o< and IL-1/3 into the culture medium during induc- 
tion of monocytic differentiation with 5 x 10-qM 
TPA. Investigation f the time course ofthis cytokine 
release by radioimmunoassay howed that the level 
of released TNF-oebecame significant by 4 h following 
TPA-treatment and reached a maximum after 48 h 
(Fig. la). In long term cultured TPA-U937 in the 
absence of TPA, maximal TNF-o< release was 
measured until day 6. Between 8days and 10 days in 
culture this TNF-o< release dropped to detection limit. 
TPA-treatment of these long term cultured TPA- 
U937 after 20 days, however, re-induced the TNF-o< 
production (Fig. lc). In contrast, he amount of TNF- 
o< in the culture medium of untreated U937 control 
cells was always at the detection limit (49 pg/ml) 
during the whole time course of the experiment (Fig. 
la). 
IL-l-production was not detectable in U937 con- 
trol cells and during the first 24 h of TPA-treatment. 
A significant release of IL-1 /3, however, was 
measured between 24 h and 48 h following addition 
of TPA and reached a maximum after 72 h (Fig. 
lb). This maximal level was continuously decreased 
during long term culture of TPA-U937 and reached 
detection limit between 20 days and 22 days. At this 
time point IL-1/5 production could be induced again 
by a further stimulation with TPA (Fig. ld), There 
was no detectable production of IL-1 o< in thc culture 
medium of either U937 or phorbol ester-treated U937 
cells at any time point of the experiments (data not 
shown). 
In order to test the bioactivity of the released TNF- 
o< and IL-1 /3 proteins the appropriate biological 
assay systems were employed. TPA (5 x 10 -'~ M) 
significantly interferred with both the TNF and IL-1 
biological assay. Therefore, itwas removed after 72 h 
by changing thc culture medium and the cytokinc 
release was measured after a further 24 h culture. 
Control experiments by labeling of U937 cclls with 
[3H]TPA, demonstrated that only a very low con- 
centration of [3H]TPA (about I()-~M) was still 
present in thesc 24 h supernatants. This amount of 
TPA did not interfere with either of the biological 
assay systems (data not shown). Measurements of
the 24 h supernatant from TPA-U937 cells by the 
indirect IL-l-assay using the EL4.16 and CTLL cell 
lines showed significant levels of biologically active 
1L-I (260pg/5 x 1115 cells). The presence of bio- 
logically active IL-I was also detected in long term 
cultured TPA-U937 (until day 16). In contrast, no 
lL-I activity was measured in the supernatant of 
undifferentiated U937 control cells. In addition, no 
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TABLE 1. CHARACTERIZATION OF MONOCYTIC MARKERS AND GROWTH ARREST 
DURING TPA-INDUCED DIFFERENTIATION OF U937 CELLS 
NBT [%] tr-NAEST [%] [3H]thymidine [%] 
U937 <1 <1 100.0 +- 7.8 
24 h TPA 3.3 -+ 0.7 84.3 - 4.7 35.2 +-- 8.2 
48 h TPA 10.3 +- 0.9 96.9 -+ 1.2 1.1 - 0.2 
72 h TPA 13.8 - 3.5 98.3 -+ 0.3 0.3 +- 0.1 
U937 cells (5 x 105 cells/ml) were treated with 5 nM TPA for the time points 
indicated. The differentiation along the monocytic pathway was investigated by 
evaluating the percentage of the different cell populations to reduce nitroblue tetra- 
zolium (NBT) [53] and to express tr-naphthylacetate esterase (tr-NAEST) [54]. Data 
represent the means -+ S.D. of three different experiments. The cell growth was 
measured by [3H]thymidine incorporation [12] and the percentage of proliferating 
cells was calculated with U937 cells as reference (U937 = 100%). Data represent the 
means -+ S.D. (n = 8). 
biological TNF-activity was detectable in the super- 
natant of undifferentiated U937 cells whereas the 
subsequent 24h supernatant from TPA-U937 
showed cytotoxic activity (150 pg TNF/5 × 105 cells) 
using the L929 cell assay and the cytotoxic activity 
was still detectable in long term cultured TPA-U937 
(until day 6). 
The sequential induction of TNF-tr and IL-1 /3 in 
U937 cells following TPA-treatment occurred inde- 
pendently as demonstrated in experiments where a 
parallel incubation of TPA-treated U937 cells with a 
monoclonal TNF-tr antibody reduced the amount of 
TNF-tr in the supernatant by 92.1% and 90.4% at 
12 h and 48 h, respectively. Under these conditions, 
IL-1 fl production was not significantly reduced. 
Accordingly, incubation of U937 cells with rhTNF-o~ 
for 24 h at concentrations between 100-3000 U/ml 
did not result in a significant release of IL-1/3 at any 
time point measured (Table 2). 
Regulation of cytokine release in TPA-differentiated 
U937 cells 
TPA-U937 were treated for 24h with different 
concentrations of either rhTNF-tr (1-1000 U/ml), 
dexamethasone (60nM-1 IxM), PGE2 (0.5ng/ml- 
3 ng/ml) or rhy-IFN (1-1000U/ml). The medium 
was changed and the subsequent 24 h and 48 h super- 
natants were collected and assayed for TNF-cr and 
IL-1 /3. The data are shown for the optimal con- 
centrations of the exogenous stimuli, including TNF- 
tr (100 U/ml), PGE2 (2 ng/ml) and rhy-IFN (100 U/ 
ml). 
Treatment of TPA-U937 with rhTNF-tr did not 
significantly alter the level of TNF-tr and IL-1 /3 
released from TPA-differentiated U937 cells (Fig. 
2). Although a slight reduction of IL-1 /3 was 
measured after 48 h this effect by TNF-o~ was not 
significant as calculated by the two sided Student 
t-test for dependent measurements. 
In addition, incubation of TPA-U937 with PGE2 
showed no significant effect on either TNF-or or IL- 
l fl release within 24 h or 48 h (Fig. 2). 
When TPA-U937 were incubated with rhy-IFN, 
the release of IL-1 fl was specifically enhanced. This 
superinduction of IL-1 fl was increased 8-10-fold 
when compared to TPA-U937 whereas the level of 
released TNF-te remained unaltered (Fig. 2). 
Dexamethasone inhibited the release of both TNF- 
and IL-1 fl from TPA-U937 in a dose-dependent 
manner. The inhibition was highly significant (all 
p < 0.01) and reached 64.2% +-- 4.9% (n = 4) for 
TNF-or and 57.0% -+- 4.2% (n = 4) for IL-1 fl com- 
pared to the 24 h release from TPA-U937 (Table 3). 
FPLC-separation of FCS-free cell supernatant of 
TPA/IFN- U937 cells 
Conditioned medium collected from TPA-U937 
treated with y-IFN was concentrated and then sep- 
arated by gel filtration FPLC. The elution pattern of 
proteins in the conditioned medium is shown in Fig. 
3. All fractions were tested for TNF-tr and IL-I fl 
using RIA. TNF-awas found in fractions with appar- 
ent molecular weight between 50 kD and 100 kD. 
Investigations of IL-1 fl containing samples, ident- 
ified proteins with molecular weight of 35 kD--45 kD 
and 10kD-20kD. All TNF- and IL-l-containing 
fractions as evaluated by RIA were also biologically 
active as measured in the appropriate assay systems. 
In addition, the IL-l-containing fractions were capa- 
ble of displacing [125I]IL-1 a" in receptor binding 
studies with the mouse thymoma cell line EL4.16 
(data not shown). 
Characterization of IL-1 fl by Western-blot analysis 
Western-blot analysis of IL-1 proteins in U937 cells 
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TABLE 2. TNF-INDEPENDENT INDUCTION OF IL-1 DURING TPA-INDUCED DIFFERENTIATION OF U937 CELLS 
2 h 12 h 48 h 
TNF-a [pg/ml] IL-1 fl [pg/ml] TNF-cr [pg/ml] IL-1 fl [pg/ml] TNF-o: [pg/ml] IL-1 fl [pg/ml] 
U937 ND ND ND ND ND ND 
U937 + TPA 390 --+ 18 ND 3349 +-- 712 77 -+ 51 3532 --+ 458 350 -+- 77 
U937 + TPA + 
mab(TNF-a~) ND ND 264 -+- 29 67 -+- 18 254 - 45 337 -+- 172 
U937 + TNF-t~ 
(100 U/ml) 2282 -+ 561 ND 794 -+ 59 ND 745 -+- 60 ND 
U937 + TNF-tr 
(300 U/ml) over ND over ND over ND 
U937 + TNF-cr 
(1000 U/ml) over ND over ND over ND 
U937 + TNF-tr 
(3000 U/ml) over ND over ND over ND 
U937 control cells were treated with either 5 x 10-gM TPA alone or with both 5 x 10 -9 M TPA and 10 p,g/ml of a 
monoclonal TNF-tr antibody (mabTNF-tr). Furthermore, control cells were incubated with different concentrations of
rhTNF-o~ for the time points indicated. The concentrations of TNF-tr and IL-1 fl in the supernatants were measured by 
RIA (detection limits: 49 pg/ml TNF-tr; 21 pg/ml IL-1 fl). Data represent means -+ S.D. (n = 4); ND = not detectable; 
over = out of range. 
~n 
u~ 
3000 
2000. 
_.L 
1000. I 
TNF--~ PGE 2 y-FN 
2/. hour supernotont 
contrd TNF-~ PGE 2 y-FN 
/.8 hour supernatant 
FIG. 2. Effects of rhTNF-tr, PGE2 and rhy-IFN on TNF-tr 
release ( I )  and IL-1 fl release (I---q). TPA-differentiated 
U937 cells (5 × 105 cells/ml) were incubated with either 
culture medium (control), 100U/mi rhTNF-o:, 2ng/ml 
PGE2 and 100 U/ml rh),-IFN for further 24 h. After remov- 
ing the stimuli the cells were cultured further on in culture 
medium and the cytokine release was measured by RIA in 
the subsequent 24 h and 48 h supernatants (detection limits: 
49 pg/ml TNF-oc; 21 pg/ml IL-1 fl). Data represent means 
-+ S.D. of 3 different experiments. 
were shown in Fig. 4a. In addition to the 18 kD rhlL- 
1 fl standard protein a strongly expressed band with 
apparent molecular weight of 33-35 kD and a high 
molecular weight protein of approximately 70 kD 
was recognized by the IL-1 fl antibody in TPA-U937,  
these proteins being even more strongly expressed in 
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TABLE 3. DOSE-DEPENDENT INHIBITION OF TNF-tI" AND IL- 1 fl RELEASE FROM TPA- 
DIFFERENTIATED U937 CELLS BY DEXAMETHASONE 
333 
TNF-tr [ pg/ml] IL-lf l  [pg/ml  
TPA-U937 
TPA-U937 + 6 x 10 -s M Dex 
TPA-U937 + 10 7 M Dex 
TPA-U937 + 3 x 10 -7 M Dex 
TPA-U937 + 6 x 10 -7 M Dex 
TPA-U937 + 106 M Dex 
4089 ± 506 1083 ± 191 
2872 -* 395 1277 +_ 240 
2079 ± 142 842 ± 15 
2224 m 288 749 + 116 
2042 -+ 168 627 -+ 78 
1463 -+ 202 463 _+ 45 
TPA-U937 (5 x 105 cells/ml) were cultured for 24 h with the concentrations of
dexamethasone indicated. The amount of released cytokines was detected by RIA 
(detection limits: 56 pg/ml TNF-o:; 81 pg/ml IL-1 fl). Data represent means ± S.D. 
(n = 4) .  
E 
c O~ 
~ O~ 
123 
0O3 
0 25 
O2 
0 15 
01 
00S 
0 1 2 3 
KD 
k 5 6 7 8 9 1(I 11 15 20 
fraction number 
15 t0 
FIG. 3. FPLC-separation of 1:1000 concentrated super- 
natant from TPA/IFN-U937 cells as described in the 
Methods section. Fractions from the gel-filtration superose 
12 column were collected in 0.5 ml aliquots. TNF-oc and 
IL-I/3 in all fractions were investigated by RIA (detection 
limit: 46 pg/ml TNF-oc; 19 pg/ml IL-1 fl). The data are 
shown for 1 representative experiment out of 4. 
= TNF-a~ containing fractions (11.5: 12). 
= IL-1 fl containing fraction (12.5). 
= IL-1 fl containing fractions (14; 14.5; 15). 
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TPA/IFN-U937. Both, the 33-35 kD and the 70 kD 
proteins were also present in the TPA/Dex-U937 
homogenate. In comparison to TPA-U937 and TPA/ 
IFN-U937, however the expression of these proteins 
was markedly reduced. The concentrated super- 
natant of TPA/IFN-U937 showed only the 35 kD 
band. After a long exposition of the blot to the X- 
ray film (>4 weeks) a very weak 18 kD band could 
be detected in this sample (data not shown). 
In a corresponding experiment a more detailed 
intracellular localization of IL-1/3 in U937 cells was 
investigated (Fig. 4b). The results demonstrate 
clearly that IL-1 fl is predominantly located in the 
cytosol of differentiated U937 cells. Furthermore, 
no IL-1 fl was detectable in undifferentiated U937 
control cells and TPA/Dex-U937 showed a markedly 
decreased expression of IL-1 fl when compared to 
TPA-U937 or even TPA/IFN-U937. 
Northern-blot analysis of TNF-tr and IL-1/3 rnRNA 
The investigation of a time course of mRNA 
expression for TNF-a" (Fig. 5a) and IL-1/3 (Fig. 5b) 
resulted in a sequential induction of both cytokines. 
A strong expression of TNF-a" mRNA was observed 
in 48 h TPA-treated U937 cells (b) compared to U937 
control cells (a). Following an extended culture of 
TPA-treated U937 cells for 7 days (c), 9 days (d) and 
12 days (e) a continuously decreasing expression of 
TNF-cr became obvious reaching again the level of 
U937 control cells after 16 days following treatment 
with TPA (f). 
In contrast to TNF-cr IL-1 fl mRNA was not detect- 
able in undifferentiated U937 cells (Fig. 5b, lane (a)). 
Following 2 days of TPA-treatment a weak band with 
apparent molecular weight of 1.8 kB became obvious 
(b), this band being markedly enhanced in TPA- 
treated U937 cells cultured for 7 days (c). The 
extended culture of TPA-treated U937 cells for 9 
days up to 16 days revealed continuously increasing 
levels of IL-1 /3 mRNA. In addition to this long 
termed IL-1 /3 signal, an increased expression of a 
high molecular weight mRNA became detectable. 
Equal loading of mRNA was determined by ethid- 
ium bromide-stained 18S and 28S RNAs (data not 
shown). 
DISCUSSION 
The human monoblastoid tumor cell line U937 is 
a model in which differentiation of precursor cells 
into macrophage-like cells can be studied 
conveniently. Upon treatment with the phorbol ester 
TPA, all U937 cells undergo significant mor- 
phological and functional changes during the dif- 
ferentiation process reaching a transient macrophage 
intermediate state rather than a terminally dif- 
ferentiated state [13, 24]. This tumor cell line was 
used to investigate and characterize induction of 
TNF, IL-1 and IL-6 production and to examine the 
regulation of these cytokines during monocytic dif- 
ferentiation. 
Within 2-4 h following TPA-treatment we 
measured a rapidly increased TNF-0~ production, 
which reached aplateau after 48-72 h and then slowly 
(within 10 days) decreased to the level of undif- 
ferentiated U937 control cells. These data are in 
accordance with the results obtained by Northern- 
blot analysis demonstrating a marked increase of 
TNF-cr mRNA after 48 h of TPA-treatment followed 
by a continuously decreasing TNF-a~ mRNA signal 
in a long term culture of TPA-U937. A similar induc- 
tion of TNF was also observed in TPA-treated resting 
macrophages, however, the maximal signal of TNF 
mRNA transcription occurred after 12 h followed by 
a decreased signal after 24 h of TPA-treatment [25]. 
In terms of IL-1 production our results show an 
enhanced level of IL-1 fl mRNA and a continuously 
increasing amount of IL-1 fl release from U937 cells 
between 24 and 48 h after incubation with TPA. This 
IL-1 fl production was still detectable after 20 days 
which is also in accordance with the IL-1 fl Northern- 
blots, demonstrating a strong signal after 13 days. 
Interestingly, Nishida et l. have shown that increas- 
ing levels of IL-1 fl mRNA are expressed already 4 h 
after TPA-treatment of U937 cells [26] and our data 
demonstrate furthermore, that transcription of IL-1 
fl messages continued to increase during long term 
culture even when the release of cytokine was sig- 
nificantly reduced. These data indicate that the tran- 
scription, translation and release of IL-1 /3 is 
regulated by different mechanisms which has also 
been observed in other systems [27]. In contrast to 
TNF-o~ and IL-1 /3, no increase in either IL-1 cr 
mRNA expression or IL-1 a release could be 
measured in TPA-treated U937 cells (data not 
shown) which is in accordance with the findings of 
Nishida et al. [26]. 
The sequential induction of TNF-a" (between 2- 
4h) and IL-1 /3 (between 24-48h) in TPA-U937 
apparently occurs independently, since neutraliz- 
ation of TPA-induced TNF-tr release by a mono- 
clonal TNF-cr antibody had neither an effect on the 
TPA-induced IL-1 fl release nor any influence on 
the ongoing differentiation process. Furthermore, 
treatment of undifferentiated U937 control cells with 
rhTNF-cr did not result in increasing IL-1 fl or IL-1 
a, release, although receptors for TNF were well 
characterized on these cells [28] and alterations in 
gene expression following TNF-treatment have been 
FIG. 4(a). IL-1 fl Western-blot analysis of the homogenate 
from stimulated U937 cells: 50 ng rhlL-1 /3 as standard 
(lane a); TPA-U937 (lane b); 1 : 1000 concentrated super- 
natant of TPA/IFN-U937 cells (lane c); TPA/IFN-U937 
(lane d); TPA/Dex-U937 (lane, e, f). Each lane except 
the standard (lane a) contained 30 p,g protein. (b) IL-1 /3 
Western-blot analysis of the cytosol (lanes a~l) and thc 
membranes (lanes e-h) of U937 control and stimulated 
cells: U937 cells (lanes a, e); TPA/U937 (lanes b, f): TPA/ 
Dex-U937 (lanes c, g); TPA/IFN-U937 (lanes d, h) and 
50 ng rhlL-1 /3 as standard (lane i). Each lane cxcept the 
standard contained 30 lag protein. 
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(b) 
FIG. 5. Northern-blot analysis of TNF-o~ mRNA (a) and 
IL-1/~ mRNA (b): U937 cells (lane a); U937 cells treated 
for 48 h with 5 x 10 -9 M TPA (lane b); TPA-U937 cultured 
for further 4 days (lane c); 6 days (lane d); 9 days (lane e) 
and 13 days (lane f). 
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described [29]. These findings suggest an inde- 
pendent induction of TNF-tr and IL-1 fl during dif- 
ferentiation of U937 cells. 
Dinarello et al. reported an induction of IL-1 
release following stimulation of human mononuclear 
cells with exogenous TNF-tr [30] and an autocrine 
TNF-induction has been described by several groups 
[31, 32]. In TPA-U937, however, no effects on TNF- 
tr and IL-1/3 release were detectable when these cells 
were stimulated with exogenously added TNF-tr. The 
lack of TPA-U937 to respond to exogenous TNF-tr 
similar to macrophages may be explained by the 
findings of Holtmann and Wallach who reported a 
rapid down-regulation of TNF-receptors in U937 
cells treated with low concentrations of TPA 
(<5 x 10-9 M) [33]. In this respect it is interesting to 
note that Brach et al. discussed IL-6 mRNA accumu- 
lation upon TNF-treatment of U937 cells [34], fur- 
thermore suggesting that after TPA-treatment U937 
cells are unable to respond to released TNF by an 
autocrine mechanism since our results revealed only 
background levels of IL-6 mRNA during the whole 
time course of the experiment (data not shown). 
Although IL-6 production by two U937 subclones 
has been recently reported, this discrepancy may be 
explained by the 16-fold higher amount of TPA used 
in the studies of Navarro et al. [35], suggesting that 
induction of the IL-6 gene may depend on the con- 
centration of TPA used but may not necessarily be 
associated with the differentiation process. 
Exogenously added PGE 2 like TNF-tr showed no 
effect on either TNF-tx or IL-I/3 release from TPA- 
U937, although an inhibition of either TNF-release 
[36] or IL-1 production [4, 37] by PGE2 has been 
described in stimulated macrophages. Taken 
together, these data point to a different cytokine 
regulation in TPA-U937 compared to activated 
monocytes/macrophages. 
Dexamethasone treatment of TPA-U937 caused a 
dose-dependent i hibition of both, TNF-cr and IL-I 
/3 release. Our data are in accordance with the find- 
ings of other groups who reported a transcriptional 
and post-transcriptional reduction of IL-I expression 
by a selectively inhibited transcription of the IL-1 /3 
gene and a decreased stability of IL-1/3 mRNA upon 
treatment with dexamethasone [38, 39]. A gluco- 
corticoid inhibited release of TNF and IL-1 in mono- 
cytes from several species has also been described 
[40-42]. 
Treatment of TPA-U937 with y-IFN resulted in 
a strongly enhanced production and an 8-10-fold 
specifically increased release of IL-1 /3, whereas the 
amount of TNF-0¢ remained unaltered. Similarly, 
Arenzana-Seisdedos et al. reported a potentiation of 
IL-1 release from human blood monocytes by y-IFN 
rather than cr-IFN and/3-IFN [43]. With respect o 
the level of released TNF-0¢, however, Nedwin et al. 
have shown in human blood monocytes that y-IFN 
was only capable of inducing TNF production in 
co-stimulation with IL-2 or mitogens [44], whereas, 
Beutler et al. also discussed a TNF induction by y- 
IFN alone in mononuclear phagocytes [45]. 
A characterization of TNF-cr and IL-1 /3 release 
from TPA/IFN-U937 by FPLC separation of con- 
centrated FCS-free conditioned medium resulted in 
TNF with apparent molecular weight of 50-100 kD 
and 2 fractions of IL-1 /3 with molecular weight of 
35-45 kD and 10-20 kD, respectively. Data obtained 
by Western-blot analysis under reducing conditions 
showed an IL-I /3 standard protein at 18 kD. In the 
samples, beside a very weak band at approximately 
18 kD, a 33-35 kD IL-1 prevailed and also a cell- 
associated high molecular weight IL-1 with 70 kD not 
found in the supernatant was detected. The pro- 
duction of a 33 kD IL-1/3 precursor protein by stimu- 
lated U937 cells has recently been reported [46]. 
Extensive studies by Knudsen et al. have shown a 
14 kD IL-I protein in the supernatant of staphy-  
lococcus exotoxin activated U937 cells with pI 5.5 
[47] which may correspond to another IL-1 form than 
those recognized by the antibody in our studies. A 
high molecular weight IL-1 with approximately 75kD 
has been discussed by Togawa et al. in human mono- 
nuclear cells [48] and has also been found in normal 
human urine [49]. 
The data clearly indicate a preferred localization 
of IL-1 /3 in the cytosol of differentiated U937 cells 
which is consistent with the findings of Rubartelli et 
al. [46] and of Sisson and Dinareilo who found most 
of the cell-associated TNF-tr, IL-1 0l and IL-1 /3 in 
the cytosol by sequential and differential cen- 
trifugation of rGM-CSF stimulated human mono- 
cytes [50]. In this respect it is interesting to note 
that Merluzzi et al. found membrane-associated IL-1- 
activity in TPA-treated U937 cells [51], suggesting 
that cytosolic inactive IL-1 precursors may be pro- 
cessed into biologically active IL-1 molecules as dis- 
cussed by Martin and Resch [52]. 
The consistency of all IL-I data, including the 
release, the FPLC-separation, the Western-blots and 
the Northern-blots suggests that TPA-U937 acquire 
the capacity to produce a 33-35 kD precursor IL-1 /3 
in large quantities and release a small amount of IL- 
l/3 with detectable biological activity, whereas about 
98% of IL-1 /3 remains located in the cytosol. It is 
still unclear whether the intracellular 70 kD IL-I /3, 
which is reduced by dexamethasone and enhanced 
expressed by y-IFN similar to the IL-1/3 release data, 
is a precursor molecule or a tightly associated imer 
of the 33-35 kD IL-1/3. 
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We therefore conclude that the sequential induc- 
tion of TNF-o~ and IL-1 /3 in U937 cells treated with 
TPA is independently regulated. Although TPA- 
U937 acquire a glucocorticoid sensitivity similar to 
macrophages, the newly described specifically super- 
induced IL-1 /3 production of TPA/ IFN-U937 and 
the unaltered levels of TNF-o: and IL-1 /3 release 
by rhTNF-a~ and PGE2 indicate differences in the 
regulation of both cytokines compared to activated 
monocytes/macrophages. The failure of TPA-U937 
to generate detectable amounts of IL-1 o~ and IL- 
6 and the production of significant levels of high 
molecular weight IL-1/3 proteins (70 kD, 33-35 kD) 
may be related to either the tumorgenicity of U937 
cells or to an intermediate state of differentiation 
upon TPA-treatment which then suggests that cyto- 
kine processing as in mature monocytes/macro- 
phages is acquired during later or terminal steps of 
maturation. 
Acknowledgements--This work was supported by the 
Deutsche Forschungsgemeinschaft SFB 244/B5. The 
authors thank Mrs Karin Molitor for her excellent technical 
assistance. 
REFERENCES 
1. Carswcll E. A., Old L. J., Kassel L., Green S., Fiore N. 
& Williamson B. (1975) An endotoxin-induced serum 
factor that causes necrosis of tumors. Proc. natl Acad. 
Sci. U.S.A, 72, 3666. 
2. Gery I. & Waksman B. H. (1972) Potentiation of the 
T-lymphocyte r sponse to mitogens. J  expl Med. 136, 
143. 
3. Hazuda D. J., Lee J. C. & Young P. R. (1988) The 
kinetics of interleukin-1 secretion from activated mono- 
cytes. J. lmmun. 263, 8473. 
4. Knudsen P. J., Dinarello C. A. & Strom T. B. (1986) 
Prostaglandins post-transcriptionally inhibit monocyte 
expression of interleukin-I activity by increasing intra- 
cellular cyclic adenosine monophosphate. J. lmmun. 
137, 3189. 
5. Kurt-Jones E. A., Virgin H. W. & Unanue E. R. 
(1987) In vivo and in vitro expression of membrane 
interleukin-1 in response to soluble particulate stimuli. 
J. lmmun. 137, 10. 
6. Myers J. M., Pullen J. K., Ghildyal N., Eustis-Turf E. 
& Schook L. B. (1989) Regulation of IL-I and TNF-a~ 
expression during the differentiation of bone marrow- 
derived macrophages. J. Immun. 142, 153. 
7. Sundstr6m C. & Nilsson K. (1976) Establishment and 
characterization f a human histiocytic lymphoma cell 
line (U937). Int. J. Cancer 17, 565. 
8. Olsson I. L. & Breitman T. R. (1982) Induction of 
differentiation of the human histiocytic lymphoma cell 
line U937 by retinoic acid and cyclic adenosine 3' : 5'- 
monophosphate-inducing agents. Cancer Res. 42, 3924. 
9. Dodd R. C., Cohen M. S., Newman S. L. & Gray T. 
K. (1983) Vitamin D metabolites change the phenotype 
of monoblastic U937 cells. Proc. natl Acad. Sci. U.S.A. 
80, 7538. 
11). llarris P. E., Ralph P., Litcofsky P. & Moore M. A. 
S. (1985) Distinct activities of interferon-),, lymphokine 
and cytokine differentiation-inducing factors acting on 
the human monoblastic leukemia cell line U937. Cancer 
Res. 45, 9. 
11. Wiederhold M. D., Anderson K. M. & Harris J. E. 
(1988) Labelling of lipids and phospholipids with 
[3H]arachidonic acid and the biosynthesis of eico- 
sanoids in U937 cells differentiated by phorbol ester. 
Biochim. biophys. Acta 959, 296. 
12. Hass R., Bartels H., Topley N., Hadam M., K6hler L., 
Goppelt-Striibe M. & Resch K. (1989) TPA-induced 
differentiation fU937 cells: Changes in ultrastructure, 
cytoskeletal organization and cell surface antigen 
expression. Eur. J. Cell Biol. 48, 282. 
13. Hass R., KOhler L., Rehfeldt W., Lel3mann V., Mtiller 
W., Resch K. & Goppelt-Striibe M. (1990) Alterations 
in glycosylation and lectin pattern during phorbol ester- 
induced differentiation of U937 cells. Cancer Res. 50, 
323. 
14. Meer van den J. W. M., Endres S., Lonnemann G., 
Cannon J. G., lkejima T., Okusawa S., Gelfand J. A. 
& Dinarello C. A. (1988) Concentrations of immu- 
noreactive human tumor necrosis factor alpha pro- 
duced by human mononuclear cells in vitro. J. 
Leukemia Biol. 43, 216. 
15. Lonnemann G., Endres S., van der Meet J. W. M., 
Ikejima T., Cannon J. G. & Dinarello C. A. (1988) 
A radioimmunoassay for human interleukin-1 alpha: 
Measurement of IL-1 alpha produced in vitro by human 
blood mononuclear cells stimulated with endotoxin. 
Lymphokine Res. 7, 75. 
16. Lisi P. J., Chu C. W., Koch G. A.. Endres S,, 
Lonnemann G. & Dinarello C. A. (1987) Development 
and use of a radioimmunoassay for human interleukin- 
l ft. Lymphokine Res. 6, 229. 
17. Wallach D. (1984) Preparations of lymphotoxin i duce 
resistance to their own cytotoxic effect. J. Immun. 132, 
2464. 
18. Bradford M. M. (1976) A rapid and sensitive method 
for the quantitation of microgram quantities of protein 
utilizing the principles of protein-dye-binding. Analyt. 
Biochem. 72, 248. 
19. Redinbaugh M. G. & Campbell W. It. (1985) Adap- 
tation of the dye-binding protein assay to microtiter 
plates. Analyt. Biochem. 147, 144. 
20. L~immli U. K. (1970) Cleavage of structural proteins 
during the assembly of the head of bacteriophage T4. 
Nature 227, 680. 
21. Khandjian E. W. (1986) UV crosslinking of RNA to 
nylon membrane enhances hybridization signals. Mol. 
Biol. ReD. 11, 107. 
22. Chirgwin J. M.. Przybyla A. E.. MacDonald R. J. & 
Rutter W. J. (1979) Isolation of biologically active 
ribonucleic acid from sources enriched in ribonuclease. 
Biochem. 18, 5294. 
23. Feinbcrg A. P. & Vogelstein B. (1983) A technique for 
radiolabeling DNA restriction endonuclease fragments 
to high specific activity. Analyt. Biochem. 132, 6. 
24. Hass R., Giese G., Meyer G., Hartmann A., D6rk T., 
K6hler L., Resch K. & Goppelt-Strtibe M. (1990) 
Differentiation and retrodifferentiation f U937 cells: 
reversible induction and suppression f intermediate 
filament protein synthesis. Eur. J. Cell Biol. 51,265. 
Cytokine production bydifferentiating U937 cells 339 
25. Sariban E., Imamura K., Luebbers R. & Kufe D. 
(1988) Transcriptional and posttranscriptional regu- 
lation of tumor necrosis factor gene expression in 
human monocytes. J. clin. Invest. 81, 1506. 
26. Nishida T., Takano M., Kawakami T., Nishino N., 
Nakai S. & Hirai Y. (1988) The transcription of the 
interleukin 1/3 gene is induced with PMA and inhibited 
with dexamethasone in U937 cells. Biochem. biophys. 
Res. Commun. 156, 269. 
27. Flad H. D., Loppnow H., Feist W., Wang M. tt., 
Brade H., Kusumoto S., Rietschel E. T. & Ulmer 
A. J. (1989) lnterleukin 1 and tumor necrosis factor: 
Studies on the induction by lipopolysaccharide partial 
structures. Lymphokine Res. 8, 235. 
28. Tsujimoto M., Feinman R., Kohase M. & Vilcek J. 
(1986) Characterization and affinity crosslinking of 
receptors for tumor necrosis factor on human ceils. 
Archs. Biochem. Biophys. 249, 563. 
29. Schiitze S., Scheurich P., Schliiter C., Ucer U., 
Pfizenmaier K. & Kr6nke M. (1988) Tumor necrosis 
factor-induced changes of gene expression in U937 
cells. J. lmmun. 140, 3000. 
30. Dinarello C. A.. Cannon J. G., Wolff S. M., Bernheim 
H. A., Beutler B., Cerami A., Figari I. S., Palldino Jr 
M. A. & O'Connor J. V. (1986) Tumor necrosis factor 
(cachectin) isan endogenous pyrogen and induces pro- 
duction of interleukin-1. J expl Med. 163, 1433. 
31. Hensel G., M~innel D. N.. Pfizenmaier K. & Kr6nke 
M. (1987) Autocrine stimulation of TNF-alpha mRNA 
expression in HL-60 cells. Lymphokine Res. 6, 119. 
32. Philip R. & Epstein L. B. (1986) Tumor necrosis factor 
as immunomodulator and mediator of monocyte cyto- 
toxicity induced by itself, gamma-interferon and 
interleukin-1. Nature 323, 86. 
33. Holtmann H. & Wallach D. (1987) Down regulation of 
the receptors for tumor necrosis factor by interleukin- 
1 and 4~phorbol-12-myristate-13-acetate. J. Immun. 
139, 1161. 
34. Brach M. A., Cicco N. A., Riedel D., Hirano T., 
Kishimoto T., Mertelsmann R. H. & Herrmann F. 
(1990) Mechanisms of differential regulation of 
interleukin-6 mRNA accumulation by tumor necrosis 
factor alpha and lymphotoxin during monocytic dif- 
ferentiation. FEBS Left. 263, 349. 
35. Navarro S.. Debili N., Bernaudin J. F., Vainchenker 
W. & Doly J. (1989) Regulation of the expression of 
IL-6 in human monocytes. J. lmmun. 142, 4339. 
36. Kunkel S. L., Wiggins R. C., Chensue S. W. & Larrick 
J. (1986) Regulation of macrophage tumor necrosis 
factor production by prostaglandin E2. Biochem. 
biophys. Res. Commun. 137, 404. 
37. Kunkel S. L., Chensue S. W. & Phan S. H. (1986) 
Prostaglandins a endogenous mediators of interleukin- 
1 production. J Immun. 136, 186. 
38. Knudsen P. J.. Dinarello C. A. & Strom T. B. (1987) 
Glucocorticoids inhibit transcriptional and posttran- 
scriptional expression of interleukin-I in U937 cells. J. 
hnmun. 139, 4129. 
39. Lee S. W., Tsou A. P., Chan H., Thomas J.. Petrie K., 
Eugui E. M. & Allison A. C. (1988) Glucocorticoids 
selectively inhibit the transcription of the interleukin- 
1/3 gene and decrease the stability of interleukin-1/3 
mRNA. Immunology 85, 1204. 
40. Beutler B., Krochin N., Milsark I. W., Luedke C. & 
Cerami A. (1986) Control of cachectin (tumor necrosis 
factor) synthesis: mechanism of endotoxin resistance. 
Science 232, 977. 
41. Kern J. A., Lamb R. J., Reed J. C., Daniele R. P. 
& Nowell P. C. (1988) Dexamethasone inhibition of 
interleukin-1 beta production by human monocytes. J. 
clin. Invest. 81,237. 
42. Snyder D. S. & Unanue E. R. (1982) Corticosteroids 
inhibit murine macrophage la expression and interleu- 
kin-1 production. J lmmun. 129, 1803. 
43. Arenzana-Seisdedos F., Virelizier J. L. & Fiers W. 
(1985) Interferons as macrophage-activating factors: 
Preferential effects of interferon-y on the interleukin- 
1 secretory potential of fresh or aged human 
monocytes. J. Immun. 134, 2444. 
44. Nedwin G. E., Svedersky L. P., Bringman T. S., 
Palladino Jr M. A. & Goeddel D. V. (1985) Effect 
of Interleukin-2, interferon-y, and mitogens on the 
production of tumor necrosis factors and Br. J. lmmu- 
nol. 135, 2492. 
45. Beutler B., Tkacenko V., Milsark I., Krochin N. & 
Cerami A. (1986) Effect of gamma-interferon on 
cachectin expression by mononuclear phagocytes: 
reversal of the lps ~ (endotoxin resistance) phenotype. 
J. expl Med. 164, 1791. 
46. Rubartelli A., Cozzolino F., Talio M. & Sitia R. (199(I) 
A novel secretory pathway for interleukin-1, a protein 
lacking a signal sequence. EMBO J. 9, 1503. 
47. Knudsen P. J., Dinarello C. A. & Strom T. B. (1986) 
Purification and characterization of a unique human 
interleukin-1 from the tumor cell line U937. J. Immun. 
136, 3311. 
48. Togawa A., Oppenheim J. J. & Mizel S. B. (1979) 
Characterization of lymphocytc-activating factor 
(LAF) produced by human mononuclear cells: bio- 
chemical relation of high and low molecular weight 
forms of LAF. J. lmmun. 122, 2112. 
49. Kimball E. S., Pickeral S. F., Oppenheim J. J. & 
Rossio J. L. (1984) Interleukin-I activity in normal 
human urine. J. lmmun. 133, 256. 
50. Sisson S. D. & Dinarello C. A. (1988) Production of 
interleukin-1, interleukin-1/3 and tumor necrosis factor 
by human mononuclear cells stimulated with gra- 
nulocyte-macrophage colony-stimulating factor. Blood 
72, 1368. 
51. Merluzzi V. J., Faanes R. B., Czajkowski M.. Last- 
Barney K., Harrison P. C., Kahn J. & Roth[ein R. 
(1987) Membrane-associated intcrlcukin-I activity on 
human U937 tumor cells: stimulation of PGE: pro- 
duction by human chondrosarcoma cells. J. lmmun. 
139, 166. 
52. Martin M. & Resch K. (1988) Interleukin 1: more than 
a mediator between leukocytes. Trends Pharmacol. 
Sci. 9, 171. 
53. Baehner R. L. & Nathan D. G. (1968) Quantitativc 
nitroblue tetrazolium test in chronic granulomatosis 
disease. New Eng. J. Med. 278, 971. 
54. Yam L., Li C. & Crosby W. (1971) Cytochcmical 
identification of monocytes and granulocytes. Am. J. 
olin. Pathol. 55, 283. 
